Zhong hua yi xue za zhi, 2024-05, Vol.104 (17), p.1507-1513
2024
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Efficacy analysis of chemotherapy and endocrine therapy combined with targeted drugs after progression on cyclin-dependent kinase 4/6 inhibitor treatment in hormone receptor positive/human epidermal growth factor receptor 2-low metastatic breast cancer
- Ist Teil von
- Zhong hua yi xue za zhi, 2024-05, Vol.104 (17), p.1507-1513
- Ort / Verlag
- China
- Erscheinungsjahr
- 2024
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- To evaluate the efficacy of chemotherapy and endocrine therapy combined with targeted drugs after progression on cyclin-dependent kinase 4/6 (CDK4/6) inhibitor treatment in hormone receptor (HR) positive/human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer. Patients with metastatic breast cancer diagnosed with HR positive/HER2 low expression at the Fifth Medical Center of PLA General Hospital from October 1, 2018 to September 30, 2023 were retrospectively included. All patients received sequential chemotherapy or sequential endocrine therapy combined with targeted drugs after progression on CDK4/6 inhibitor treatment.The median follow-up was 9 months, and the follow-up ended on October 31, 2023. The patients were divided into chemotherapy group (receiving sequential chemotherapy) and endocrine therapy group (receiving sequential endocrine therapy combined with targeted drugs), according to the treatment plan. Information on demographic data, clinical and pathological diagnosis, treatme
- Sprache
- Chinesisch
- Identifikatoren
- ISSN: 0376-2491DOI: 10.3760/cma.j.cn112137-20240207-00296Titel-ID: cdi_proquest_miscellaneous_3051425258
- Format
- –
- Schlagworte
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols - therapeutic use, Breast Neoplasms - drug therapy, Breast Neoplasms - metabolism, Breast Neoplasms - pathology, Cyclin-Dependent Kinase 4 - antagonists & inhibitors, Cyclin-Dependent Kinase 4 - metabolism, Cyclin-Dependent Kinase 6 - metabolism, Female, Humans, Middle Aged, Neoplasm Metastasis, Protein Kinase Inhibitors - therapeutic use, Receptor, ErbB-2 - metabolism, Receptors, Progesterone - metabolism